跳至主要内容
临床试验/NL-OMON44416
NL-OMON44416已完成不适用

A single-center, randomized, investigator/subject-blind, adaptive single-ascending dose (Part 1) and multiple-ascending dose (Part 2), placebo-controlled, parallel study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of RO6889450 following oral administration in healthy subjects. - RO6889450 SAD/MAD study

F. Hoffmann-La Roche Ltd.0 个研究点目标入组 164 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
164

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • healthy male or female volunteers
  • 18 - 45 years, inclusive
  • BMI 18 - 30 kilogram/meter2, inclusive
  • non-smoking

排除标准

  • Suffering from hepatitis B, hepatitis C, cancer or HIV/AIDS. In case of participation in another drug study within 90 days before the start of this study or being a blood donor within 60 days from the start of the study. In case of donating more than 1.5 liters of blood in the 10 months prior the start of this study.

研究者

相似试验